Valeant Pharmaceuticals posted improved second-quarter results and again made its case to acquire Allergan, but its financial guidance hurt shares.
WSJ.com: US Business, Wall Street Journal: Business
Thu, 07/31/2014 - 4:47pm
Valeant Pharmaceuticals posted improved second-quarter results and again made its case to acquire Allergan, but its financial guidance hurt shares.